Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 23,809,524 SHARES OF ITS COMMON STOCK AT A PRICE OF $4.20 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE 7,142,857 SHARES OF COMMON STOCK AT A PRICE OF $4.199 PER PRE-FUNDED WARRANT, IN EACH CASE, BEFORE DEDUCTING UNDERWRITING DIS.

SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OF.

SAVARA ANNOUNCES PROPOSED PUBLIC OFFERING

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, ANNOUNCED A $75 MILLION ROYALTY FUNDING AGREEMENT WITH FUNDS MANAGED BY RTW INVESTMENTS, LP (RTW), SUBJECT TO FDA APPROVAL OF MOLBREEVI. THIS NON-DILUTIVE STRATEGIC FINANCING WILL SUPPORT THE U.S. LAUNCH OF MOLBREEVI, ASSUMING FDA APPROVAL, AND ALLOW US TO FURTHER INVEST IN COMMERCIAL PRIORITIES, SAID MATT PAULS, J.D., M.B.A., CHAIR AND CH.

SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 28, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

LOS ANGELES , OCT. 27, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SVRA SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK, OCT. 23, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN SAVARA INC. ("SAVARA INC." OR THE "COMPANY") (NASDAQ: SVRA) OF A CLASS ACTION SECURITIES LAWSUIT.

INVESTORS IN SAVARA INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS  SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFSAVARA INC. (NASDAQ: SVRA). SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS - SVRA

LOS ANGELES , OCT. 23, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LOS ANGELES , OCT. 20, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED YASMINE WASFI, M.D., PH.D., FCCP HAS BEEN PROMOTED TO CMO, EFFECTIVE IMMEDIATELY. SHE SUCCEEDS RAY PRATT, M.D., FACP WHO WILL TRANSITION FROM HIS CURRENT ROLE TO SENIOR MEDICAL ADVISOR. DR. WASFI WILL REPORT DIRECTLY TO THE COMPANY'S CHAIR AND CHIEF EXECUTIVE OFFICER AND WILL SERVE AS A MEMBER OF THE EXECUTIVE LEADERSHIP TEAM.

SAVARA ANNOUNCES CHIEF MEDICAL OFFICER (CMO) TRANSITION

NEW YORK, OCT. 16, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFSAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS  SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 15, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

THE COMPLAINT ALLEGES SAVARA HID THAT ITS MOLBREEVI BLA LACKED KEY DATA, MAKING FDA APPROVAL AND TIMELY SUBMISSION UNLIKELY AND RAISING FUNDING RISKS.

SAVARA DEADLINE REMINDER: BRAGAR EAGEL & SQUIRE, P.C. REMINDS SAVARA INVESTORS TO CONTACT THE FIRM BEFORE THE NOVEMBER 7TH DEADLINE

LOS ANGELES , OCT. 13, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SVRA INVESTOR NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK , OCT. 10, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN SAVARA INC. ("SAVARA INC." OR THE "COMPANY") (NASDAQ: SVRA) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF SAVARA INC. INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 4, 2024 AND MAY 23, 2025.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION - SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 9, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SVRA DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

LOS ANGELES , OCT. 7, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 3, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE ACCEPTANCE OF TWO ABSTRACTS FOR POSTER PRESENTATION AND ONE ABSTRACT AS AN ORAL PRESENTATION AT CHEST 2025 IN CHICAGO, ILLINOIS, OCTOBER 19-22. THE COMPANY WILL ALSO HOST A LEARNING THEATRE TITLED ADVANCES IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS AT THE MEETING WHICH IS OPEN TO ALL REGISTERED CONFERENCE ATTENDEES. C.

SAVARA ANNOUNCES ENCORE PRESENTATIONS OF RESULTS FROM THE PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT CHEST 2025

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 2, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

LOS ANGELES , OCT. 2, 2025 /PRNEWSWIRE/ --THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF SAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION  SVRA

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (THE COMPANY) (NASDAQ: SVRA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED ADDITIONAL ANALYSES FROM ITS PIVOTAL PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM IN APAP WERE PRESENTED AS POSTER PRESENTATIONS AT THE ERS CONGRESS 2025 IN AMSTERDAM, THE NETHERLANDS. ERS 2025 POSTERS SAVARA TITLE: EFFICACY OF INHALED MOLGRAMOSTIM ACCORDING TO SEVERITY OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP).

SAVARA PRESENTS NEW DATA FROM THE PHASE 3 IMPALA-2 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2025

LOS ANGELES , SEPT. 25, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION.

LOS ANGELES--(BUSINESS WIRE)--SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SVRA.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SVRA

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK, SEPT. 18, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF SAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS  SVRA

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT AN INVESTOR FILED A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF SAVARA INC. (NASDAQ: SVRA), BETWEEN MARCH 7, 2024 AND MAY 23, 2025, BOTH DATES INCLUSIVE (THE CLASS PERIOD). SAVARA IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW FIRM IS INVESTIGATING THE ALLEGA.

ROSEN LAW FIRM URGES SAVARA INC. (NASDAQ: SVRA) STOCKHOLDERS WITH LARGE LOSSES TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK--(BUSINESS WIRE)---- $SVRA #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. (SAVARA OR THE COMPANY) (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. THE FIRM HAS RE.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (THE COMPANY) (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED AN INCREASED ESTIMATE OF AUTOIMMUNE PAP DIAGNOSED PREVALENCE IN THE U.S. THE UPDATED ANALYSIS INDICATES AN ~50% LARGER AUTOIMMUNE PAP PATIENT POPULATION IN THE U.S. THAN THE COMPANY'S PREVIOUSLY ESTIMATED CLAIMS ANALYSIS FROM 2023 (~5,500 AUTOIMMUNE PAP PATIENTS VERSUS ~3,600). THE RECENT ANALYSIS OF HEALTH CLAIMS DATA WAS.

SAVARA ANNOUNCES NEW U.S. HEALTH CLAIMS DATA ANALYSIS FINDS OVER 50% INCREASE IN THE ESTIMATED NUMBER OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) PATIENTS COMPARED TO PREVIOUS CLAIMS ANALYSIS

Savara Inc.

SVRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Savara Inc.

SVRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SVRA